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ABSTRACT
Osteogenesis imperfecta (OI) is a genetic disorder of connective tissue characterized by bone fragility and alteration in synthesis and
posttranslational modification of type I collagen. Autosomal dominant OI is caused by mutations in the genes (COL1A1 or COL1A2)
encoding the chains of type I collagen. Bruck syndrome is a recessive disorder featuring congenital contractures in addition to bone
fragility; Bruck syndrome type 2 is caused by mutations in PLOD2 encoding collagen lysyl hydroxylase, whereas Bruck syndrome type 1
has been mapped to chromosome 17, with evidence suggesting region 17p12, but the gene has remained elusive so far. Recently, the
molecular spectrum of OI has been expanded with the description of the basis of a unique posttranslational modification of type I
procollagen, that is, 3-prolyl-hydroxylation. Three proteins, cartilage-associated protein (CRTAP), prolyl-3-hydroxylase-1 (P3H1, encoded
by the LEPRE1 gene), and the prolyl cis-trans isomerase cyclophilin-B (PPIB), form a complex that is required for fibrillar collagen 3-prolyl-
hydroxylation, and mutations in each gene have been shown to cause recessive forms of OI. Since then, an additional putative collagen
chaperone complex, composed of FKBP10 (also known as FKBP65) and SERPINH1 (also known as HSP47), also has been shown to be
mutated in recessive OI. Here we describe five families with OI-like bone fragility in association with congenital contractures who all had
FKBP10mutations. Therefore, we conclude that FKBP10mutations are a cause of recessive osteogenesis imperfecta and Bruck syndrome,
possibly Bruck syndrome Type 1 since the location on chromosome 17 has not been definitely localized.  2011 American Society for
Bone and Mineral Research.
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Introduction
Type I procollagen undergoes multiple intracellular andextracellular posttranslational modifications. Mutations in
genes encoding type I procollagen or proteins responsible for
posttranslational modifications of the type I collagen hetero-
trimer may result in the brittle bone disorder osteogenesis
imperfecta (OI). Classic OI, an autosomal dominant heritable
disorder, has been linked to mutations in the COL1A1 and
COL1A2 genes, which code for procollagen a components of the
type I collagen heterotrimer [a1(I)2 and a2(I)1]. After assembly of
type I procollagen in the endoplasmic reticulum (ER), two a1
chains [a1(I)2] and one a2 chain [a2(I)1] become noncovalently
linked at their carboxyl-terminus. This is followed shortly by
interchain disulfide bond formation by protein-disulfide iso-
merase (PDI). The unfolded chains then undergo 4-prolyl-
hydroxylation, 3-prolyl-hydroxylation, and lysyl hydroxylation
that is then followed by assembly of the triple helix. Recently,
new proteins involved in posttranslational modification of
collagen have been implicated in recessively inherited forms
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of OI (Fig. 1). Specifically, a complex responsible for 3-prolyl-
hydroxylation composed of cartilage-associated protein
(CRTAP)/prolyl-3-hydroxylase (P3H1, encoded by the LEPRE1
gene)/cyclophilin B (PPIB) has been implicated in causing
recessive OI.(1–4) Furthermore, mutations in all three proteins
now have been shown to cause recessive forms of OI in part by
leading to loss of hydroxylation at proline residue 986 of the a1(I)
triple-helical domain and subsequent collagen overmodification.
Finally, proteins responsible for chaperoning collagen through
the ER have been implicated in recessive OI cases that do not
show evidence of collagen overmodification. The FK506 binding
protein 10 (FKBP10) and SERPINH1 ER-resident chaperone
complex have specifically been found to cause recessive OI.(5,6)
Bruck syndrome is a rare autosomal recessive disorder that
is phenotypically related to OI. The characteristics of Bruck
syndrome include bone fragility, congenital joint contractures
with webbing (pterygia), scoliosis, and osteoporosis (Table 1).
Bruck syndrome is further delineated into type 1 and type 2,
which are phenotypically indistinguishable, and discussed in
more detail below. Previously, it has been suggested that this
disorder is related to decreased posttranslational cross-linking of
collagen fibrils.(7). Collagen typically is stabilized into fibrils by
lysyl oxidation of lysine to aldehyde allysine and hydroxylysine
to aldehyde hydroxyallysine.(8–11) By either pathway, mature
cross-links of hydroxylysylpyridinoline or lysylpyridinoline are
formed.(12) Furthermore, the molecular defect in Bruck syndrome
was described to be associated with aberrant cross-linking of
bone collagen owing to underhydroxylation, whereas cartilage
and ligamentous collagen maintained normal cross-linking.(7)
A single consanguineous family was shown to have linkage to
17p12, which was the first proposed site for the gene encoding
for the bone-specific telopeptide lysyl hydroxylase.(7,13) However,
in 2003, Van der Slot and colleagues described two independent
families with mutations in the PLOD2 gene who had been
diagnosed with Bruck syndrome by biochemical analysis of their
bone showing decreased pyridinoline cross-linking.(14) PLOD2 is
a member of the PLOD family of proteins responsible for lysyl
hydroxylation and in whichmutations have been shown to cause
Ehlers-Danlos syndrome as well as Bruck syndrome type 2.
PLOD2 specifically functions as a telopeptide lysyl hydroxylase.
However, these cases showed no linkage to the previously
described chromosome 17p12 site because the PLOD2 gene
maps to 3q23-24. Van der Slot and colleagues thus proposed that
cases of Bruck syndrome linked to 17p12 and those linked to
3q23-24 (caused by mutations in the PLOD2 gene) be termed
Bruck syndrome 1 and Bruck syndrome 2, respectively.(14)
Previous studies have suggested that FKBP10 may have
multiple innate functions, including peptidylprolyl cis-trans
isomerase (PPIase) and chaperone capability. Further, these
studies have elucidated that the PPIase activity of FKBP10
functions in folding of proline-rich tropoelastin.(15) With regard to
the folding of the type I collagen heterotrimer, the activity of
the FKBP10 PPIase may be marginal.(16) In vitro, FKBP10 in
conjunction with SERPINH1 has been shown to act as chaperone
of the collagen heterotrimer.(17) Further, SERPINH1 null fibro-
blasts have demonstrated deficient fibrillogenesis with aggrega-
tion of type I collagen in the ER.(18) Loss of the FKBP10/SERPINH1
complex owing to deletion of the SERPINH1 gene was shown
originally to cause recessive OI in a dachshund model.(19)
However, SERPINH1 mutations in humans had not been
identified until the very recent report of a single child with
the phenotype of OI type 3. The child was found to have a
homozygous missense mutation in the coding region of
SERPINH1.(5)
Novel mutations in FKBP10 have been reported recently to
cause a recessive OI-like phenotype in humans. In a cohort of five
consanguineous Turkish families and one Mexican-American
family, FKBP10mutations were found to cause moderately severe
recessive OI. The OI phenotype demonstrated recurrent long
bone fractures beginning in infancy, with eventual need for a
wheelchair in early childhood. Affected patients further
demonstrated progressive kyphoscoliosis, severe osteopenia,
ligamentous laxity, grayish-white sclera, normal hearing, and
normal teeth. An iliac crest biopsy demonstrated a ‘‘fish scale’’
pattern in one patient under polarized-light histology.(6)
Taking into account the results of Alanay and colleagues and
Christensen and colleagues, there are now three classes of
mechanisms for generating an OI phenotype.(5,6) First, mutations
in the COL1A1 or COL1A2 gene may cause quantitative and/or
qualitative defects in type I procollagen leading to dominantly
inherited OI.(22,23) Second, posttranslational modification of type
I procollagen is also critical to forming properly functioning
collagen helices. Disease-causing mutations have been found in
all three genes coding for the P3H1/CRTAP/cyclophilin B protein
complex, which is responsible for fibrillar collagen prolyl-3-
hydroxylation. Finally, with the discovery of disease-causing
FKBP10 and SERPINH1mutations, defects in ER chaperone protein
complexes have been noted to cause recessive OI.
Here we present five families with a moderately severe OI
phenotype in association with some patients having congenital
contractures of the knees, ankles, and/or elbows. In all but one
family, at least one child eventually was diagnosed with Bruck
syndrome type 1. In one family we found significant evidence of
Fig. 1. Components of the posttranslational modification machinery of
type I collagen causing osteogenesis imperfecta and Bruck syndrome.
Figure depicts proteins involved in posttranslational modification of type
I collagen and mutated in osteogenesis imperfecta (OI) or Bruck syn-
drome. Mutations in genes (COL1A1 and COL1A2) encoding the a1 and a2
chains of type I procollagen most commonly result in dominant OI and
rarely recessive OI. Other rare causes of recessive OI have been shown to
be caused by mutations in genes encoding the CRTAP/P3H1/cyclophilin
B or SERPINH1/FKBP10 protein complexes. These proteins modify col-
lagen by 3-prolyl-hydroxylation and serve as endoplasmic reticulum
chaperones, respectively. Bruck syndrome is also caused by mutations
in genes coding for proteins involved in posttranslational modification of
collagen, specifically lysyl hydroxylation. The figure was produced using
Servier Medical Art: www.servier.com/Smart/ImageBank.aspx?id_¼ 729.
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variable expressivity, with one child with Bruck syndrome,
whereas his sister presented with conventional OI type 3.
Diagnosis of Bruck syndrome depended on clinical and
laboratory findings, including urine lysyl oxidation assays,
negative screens for mutations in the PLOD2 gene, and the
finding of congenital contractures in the presence of bone
fragility. Therefore, we propose that mutations in FKBP10 may
be responsible for cases of type 1 Bruck syndrome presenting
with a recessive, moderately severe OI phenotype. Further, we
propose that given phenotypic variations within family members
having the same genotype, Bruck syndrome type 1 in fact may
be a variant of the larger OI spectrum.
Methods
Patients
A total of 67 patients were selected for screening based on
reported consanguinity, familial origination in a region known
for increased rates of consanguinity, multiple affected siblings
from the same family, failure to identify mutations in the COL1A1
or COL1A2 gene, and absence of disease-causing mutations
in known genes related to recessive OI, including CRTAP and
LEPRE1. Of the 67 patients screened, 57 patients were index
cases, and 10 were family members related to the index cases.
With institutional review board approvals, blood, fibroblasts, or
tissue was collected from affected individuals, and DNA was
prepared by standard protocols. Patient histories were reviewed
following direct history/examination by the clinical coauthors.
The age of presentation listed in each case study is the most
recent patient age for clinical data review.
PCR and sequence analysis
The 10 exons of FKBP10, as well as surrounding intronic regions,
were amplified from genomic DNA patient samples by PCR and
analyzed by fluorescent dye terminator sequencing (Agencourt
Bioscience Services, a Division of Beckman Coulter Genomics,
Danvers, MA, USA) or by sequencing on the ABI3730XL apparatus
from Applied BioSystems, Inc. (Foster City, CA, USA). Results
were analyzed using Sequencher 4.8 software (Gene Codes
Corporation, Ann Arbor, MI, USA) or SeqScape software (Applied
BioSystems). Patient sequences were compared with the
Ensembl gene sequence ENSG00000141756 for FKBP10. Pre-
viously known single-nucleotide polymorphisms (SNPs) were
identified by comparison with the GeneCards database, which
includes the dbSNP, and removed from further analysis
(www.genecards.org; Weizmann Institute of Science, Rehovot,
Israel). The novel variants described as mutations in FKBP10 are
not found in the dbSNP, presently the most comprehensive SNP
database, indicating that they have not been found previously
unless otherwise noted. We have employed the conventional
coding sequence numbering in which the A of the initiator
methionine codon (AUG) is the first nucleotide (þ1), and the
initiator methionine is the first amino acid (þ1). To aid in
interpretation, this is identical to the coding system employed by
Alanay and colleagues.(6)
Clinical Vignettes
Among the 67 total cases screened for mutations in FKBP10, we
identified five unrelated families with six affected individuals.
The clinical history of the patient in case 5 has been included in
two previous publications.(20,21) Also, the clinical histories of the
two patients in case 3 and case 4 have been reported previously
in 2005.(20) The four patients identified in cases 1 through 4 had
homozygous mutations (Fig. 2), whereas the patients in cases
5 and 6 demonstrated compound heterozygous mutations
(Figs. 3 and 4).
Case 1
This patient is the only daughter of a consanguineous Turkish
marriage (first-generation cousins). She has one unaffected
sibling, and both parents were asymptomatic. She presented
at age 6 years with a history of bilateral congenital flexion
contractures of the knees with internal deviation and bilateral
extension contracture of the ankles (Fig. 5). Additionally, she had
a triangular face and somewhat rhizomelic proximal extremities.
Notably, her dentition, hearing, intelligence, and sclerae were
normal. Beginning at 2 months of age, she experienced multiple
recurrent femoral and costal fractures. At the age of 9 years, her
limb movement was found to be greatly restricted, with upper
better than lower extremities. Further, she was able to ambulate
only by wheelchair.
In addition to her clinical history, the patient’s past laboratory
history included biochemical analysis of type I collagen, which
demonstrated no obvious quantitative or qualitative abnorm-
alities. Additionally, given the presence of congenital contrac-
tures, she was assayed for urine lysyl hydroxylation defects. A
Table 1. Clinical and Phenotypic Comparison of Bruck Syndrome and Osteogenesis Imperfecta
Classic osteogenesis imperfecta type 1 Osteogenesis imperfecta type 3 Bruck syndromea
Bone fragility þ þþ þþ
Osteoporosis þ þþ þþ
Blue/gray sclera þ/ þ/ þ/
Dentinogenesis imperfecta þ/ þ/ 
Hearing loss þþ þ/ 
Congenital ptygeria   þþþ
aType 1 and type 2 Bruck syndrome are clinically indistinguishable.
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positive urine screen prompted screening for PLOD2 mutations.
However, no PLOD2 mutations were discovered. Sequencing
of FKBP10 revealed a homozygous 1-base-pair duplication
(c.831dup), which is the same as reported by Alanay and
colleagues. This mutation is predicted to lead to a frameshift
mutation and premature protein truncation (Fig. 2).
Case 2
This patient is the daughter of consanguineous unaffected
Indian Punjabi parents. She was born at term, with a length of
50 cm, weight of 3200 g, and an occipitofrontal circumference
(OFC) of 34 cm. Her developmental milestones were normal.
There was no notation of congenital contractures. At the age of
3 years, she sustained five fractures following minor trauma,
including two fractures of the humerus, as well as fractures to the
mandible, tibia, and ankle. At 5 years of age, she presented to us
for clinical evaluation with failure to thrive. She was noted to
have bluish sclerae and suffered growth retardation (length was
less than the 25th percentile at age 1 year, less than the 20th
percentile at age 3 years, less than the 1.5th percentile at age
6 years). At the time of the most recent clinical assessment, she
was 22 years of age. X-rays reveal multiple wormian bones,
kyphoscoliosis, and gracile fibulas. She has short stature (136 cm,
–4 SD), but her sclerae are no longer bluish. She has no notable
contractures. Sequence analysis for FKBP10 revealed a homo-
zygous 35-base-pair deletion (Fig. 2) resulting in a frameshift and
premature stop codon p.(Leu41Glnfs22).
Case 3
This patient is the third child of consanguineous South African
Venda parents (second-generation cousins). Neither parent was
affected, nor were three siblings. The patient had one sister, gML,
who is described as case 4. At birth, the patient was found to be
growth restricted, with a length of 39 cm, weight of 2580 g, and
an OFC of 35.5 cm (less than 3rd percentile). He was given an
initial diagnosis of arthrogryposis multiplex congenita owing to
Fig. 3. Sequencing results of FKBP10 mutations in a compound hetero-
zygote (case 5). The pedigree of case 5 is aligned directly above her
chromatograms, demonstrating two separate mutations in FKBP10. The
first change (left) is a single-nucleotide base-pair duplication (c.831dup)
that results in a frameshift mutation. The second (right) is a single-
nucleotide base pair duplication (c.1276dup) that results in a frameshift
mutation. Below the patient chromatogram is a control chromatogram
aligned to depict a wild-type DNA sequence at the exact position of the
patient mutations.
Fig. 2. Sequencing results of FKBP10 mutations (cases 1 through 4). Patient pedigrees are aligned above patient chromatograms, demonstrating their
respective mutation in FKBP10. Below the patient chromatogram is a control chromatogram aligned to depict wild-type DNA sequence at the position of
patient mutations. Cases 1 and 2 and siblings, cases 3 and 4, are depicted. Red boxes represent nucleotide base pair insertions. Dashed red lines represent
junctional sites, where a deletion has occurred (red arrows indicate direction of junctioning). Asterisks (*) depict patients with DNA available for
sequencing. The mutation for each patient is listed beneath his or her respective chromatogram.
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congenital contractures of the bilateral elbows, wrists, and knees
and a bilateral thumb-in-palm deformity. He had pterygia of
the knees bilaterally. Beginning at 2 months of age, he suffered
multiple recurrent fractures of the extremity long bones
following trivial trauma, and radiographs eventually demon-
strated wormian bones. He had normal sclerae and dentition.
Based on the findings of congenital contractures and brittle bone
disease, a diagnosis of Bruck syndromewasmade. Sequencing of
FKBP10 revealed the same homozygous 1-base-pair duplication
(c.831dup) as seen in case 1 and described by Alanay and
colleagues (Fig. 2).
Case 4
This patient is the elder sister of the patient in case 3. No
congenital contractures have been noted in her history.
Beginning at 2 months of age, she suffered multiple recurrent
fractures of the long bones of the extremities, including bilateral
femurs, left humerus, and left tibia. She was of notably short
stature, with normal sclerae, normal dentition, and a triangular
facies. At the age of 4 years, wormian bones were discovered on
skull radiographs. She was diagnosed at that time with OI type 3.
At the age of 10 years, she presented with marked growth
retardation and was 104 cm in height (less than 3rd percentile)
and 20 kg in weight. She had normal hearing and intelligence.
Sequencing of FKBP10 revealed a homozygous 1-base-pair
duplication (c.831dup), as in her sibling (Fig. 2).
Case 5
This patient is the only affected daughter of nonconsanguineous
South African parents, with five normal siblings. She was
diagnosed with ‘‘atypical’’ arthrogryposis multiplex congenita
shortly after birth owing to the presence of congenital
contractures. The diagnosis was later changed to Bruck
syndrome because of recurrent fractures typical of OI type 3.
She suffered multiple fractures of the long bones of both the
upper and lower extremities. Further, radiographs demonstrated
the presence of wormian bones in the skull. After reaching
skeletal maturity, her fracture rate reportedly decreased.
However, she suffered multiple fractures of the right tibia to
the age of 27 years. At last follow-up, she was 31 years of agewith
limited mobility. She was employed full-time in a clerical position
with relative independence using crutches and a wheelchair.
Fig. 4. Sequencing results of FKBP10 mutations in a compound hetero-
zygote (case 6). The pedigree of the patient in case 6 is aligned directly
above his chromatograms, demonstrating two separate mutations in
FKBP10. The first change (left) is a single-nucleotide base pair duplication
(c.831dup) that results in a frameshift mutation. The second (right) is a
single-nucleotide missense mutation (c.344G>A) that results in an
amino acid change p.Arg115Gln and was excluded from 100 control
samples. Below the patient chromatogram is a control chromatogram
aligned to depict wild-type DNA sequence at the exact position of the
patient mutations.
Fig. 5. Radiographic features of an affected proband with a mutation
of FKBP10. Plain radiographic films demonstrate the patient in case 1 at
7 years of age. Her skull (A) shows evidence of osteopenia and wormian
bones. Her upper and lower limbs (B, C) show evidence of contractures
and deformity owing to recurrent fractures. The pelvis (D) shows the
proximal femurs with osteopenia, regional lucencies, and deformity.
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Ambulation remained very difficult, and gait with crutches
remained abnormal. Sequence analysis for FKBP10 mutations
demonstrated a compound heterozygous genotype. In addition
to an insertion in exon 5 p.(Gly278Argfs95), a mutation locus
that was described previously by Alanay and colleagues
in a different patient, she had a second single-nucleotide
duplication (c.1276dup) resulting in a frameshift mutation
p.(Glu426Argfs54) and premature protein truncation in exon
8 (Fig. 3).
Case 6
This patient is the first child of a healthy nonconsanguineous
couple of Caucasian origin. She was born following a normal
pregnancy and found to have bilateral clubfeet and multiple
congenital contractures at birth. During the first weeks of life,
she suffered multiple pathologic fractures. Clinical examination
at 16 months of age revealed a relatively short stature (76 cm,
between the 3rd and 10th percentile), a weight of 9950 g (10th
percentile), and head circumference of 46.5 cm (between the 3rd
and 10th percentile). At 5 years of age, she presented for clinical
evaluation of failure to thrive. Despite a normal skeletal survey,
apart from multiple wormian bones on skull X-rays, because of
her personal history of several bone fractures, a provisional
diagnosis of OI was given. She had brachycephaly and a
triangular face. Her sclerae were white, and there were no signs
of dentinogenesis imperfecta. She demonstrated mild contrac-
tures of the knees bilaterally and pedes plano valgi. Biochemical
analysis of type I collagen and molecular analysis of the COL1A1
and COL1A2 genes were normal. Evaluation of the FKBP10
gene revealed compound heterozygous mutations: a nonsense
p.(Gly278Argfs95) and a missense p.(Arg115Gln) mutation
(Fig. 4).
Discussion
In contrast to the patients with FKBP10 mutations described by
Alanay and colleagues, the patients presented in these studies
demonstrated a high incidence of congenital large joint
contractures consistent with the diagnosis of Bruck syndrome.
Bruck syndrome is an OI-like syndrome consisting of osteopenia,
recurrent fractures, and congenital joint contractures. Bruck
syndrome is named after the German physician of the same
namewho reported a patient with OI who secondarily developed
large joint contractures later in life. It has been suggested
previously that the name Bruck syndrome is in fact erroneous
because of the absence of congenital contractures in Dr Bruck’s
original case.(24) Bruck syndrome has been linked independently
to chromosome 17, possibly region 17p12, and 3q23-24,
representing type 1 and type 2 Bruck syndrome, respectively.
Type 2 Bruck syndrome has been associated with mutations in
the PLOD2 gene, whereas the etiology of type 1 Bruck syndrome
has been unknown. FKBP10 is localized to chromosome 17q21.2
different than the preliminary localization for the original type I
Bruck syndrome family. However, because only chromosomes
other than 17 were definitively excluded in that family, whether
FBKP10 accounts for type I Bruck syndrome there will depend on
direct testing of that family. Here we present five independent
probands diagnosed with Bruck syndrome. These patients were
found to be negative for mutations in the PLOD2 gene. In each
case, we identified mutations in the coding region of FKBP10,
demonstrating that mutations in this gene may be responsible
for a moderately severe recessive OI phenotype with congenital
contractures. Interestingly, the siblings reported in cases 3 and
4 were diagnosed with different diseases based on current
classification of brittle bone disease. Further, case 2 also was
diagnosed with OI. These case phenotypes underscore the
difficulty in relating clinical diagnoses to molecular defects. Such
variability has not been noted so far for PLOD2-associated Bruck
syndrome type 2, where several affected individuals have had a
consistent phenotype of congenital pterygia associated with
moderate to severe bone fragility.(24)
Patients with FKBP10 mutations present a phenotype
characterized by a variable degree of bone fragility with or
without (congenital) contractures. This fact indeed suggests that
Bruck syndrome falls within the spectrum of OI phenotypes and
is not a distinct biochemical disorder, which is illustrated in the
patients in the cases presented here, who show both inter- and
intrafamilial variability in presentation. The OI phenotype in all
patients with FKBP10mutations reported so far is milder than the
severe-to-lethal recessive OI phenotypes caused by mutations in
the genes of the prolyl-3-hydroxylation complex (CRTAP, LEPRE1,
or PPIB). Moreover, the phenotypes of the patients who have
reached adulthood seem to improve and appear also generally
milder than OI type 3 caused by classic autosomal dominant
COL1A1/COL1A2 mutations.
The addition of FKBP10 and SERPINH1 to the spectrum of
OI-causing genes further adds to our knowledge of collagen
posttranslational processing and emphasizes the complexity of
dynamic bone formation and function. Again, further research is
needed to clarify the full spectrum of OI and the role of collagen
modifiers and chaperones in OI development.
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